Introduction {#Sec1}
============

Cancer pain is a major health problem, affecting up to 30% of patients with early-stage cancer, and 65--85% of patients with advanced disease \[[@CR1]--[@CR4]\]. Furthermore, at least one-third of patients with cancer pain classify it as moderate or severe \[[@CR3], [@CR5]\] and many patients do not receive adequate pain management \[[@CR6]\].

The neurophysiology of cancer pain is complex and includes inflammatory, neuropathic, ischemic, and compressive mechanisms \[[@CR7]\]. Pain in patients with cancer can be caused directly by the cancer or can be due to treatment or associated comorbidities. Correctly identifying the underlying cause of the pain will likely to lead to more appropriate pain management strategies \[[@CR8], [@CR9]\]. This is particularly important for neuropathic cancer pain, which is more likely to be caused by treatment or comorbid disease, and is more difficult to treat than nociceptive cancer pain \[[@CR8], [@CR9]\].

Compared with the general population, neuropathic pain has been studied in much less detail in patients with cancer \[[@CR9]\]. The prevalence of neuropathic pain in patients with cancer varies from 19% to 39.1%, depending on whether or not patients with mixed pain as well as pure neuropathic pain are included in the definition \[[@CR8]\]. Neuropathic cancer pain is under-reported, under-diagnosed, and under-treated, and other treatment strategies are needed in addition to opioid analgesia for optimal pain management \[[@CR8], [@CR9]\]. Furthermore, the intrathecal administration of drugs should be considered in patients with chronic moderate-to-severe pain when other less-invasive therapies fail or if they produce intolerable adverse events \[[@CR10]--[@CR12]\]. The intrathecally administered non-opioid analgesic ziconotide, a conopeptide that acts by selectively blocking N-type calcium channels, is approved in the United States in patients with severe chronic pain that is refractory to other treatments \[[@CR13]\], and in Europe in patients with severe chronic pain requiring intrathecal analgesia for pain control \[[@CR14]\]. Ziconotide can be used in combination with other intrathecal drugs, and there are studies that suggest that it has an additive analgesic effect with opioids, with minimal risk of developing dependence or tolerance \[[@CR15]--[@CR23]\].

The 2012 Polyanalgesic Consensus Conference (PACC) polyanalgesic algorithm for intrathecal drug delivery in the management of pain recommends ziconotide as first-line intrathecal treatment options for chronic refractory nociceptive, mixed, or neuropathic pain \[[@CR10]\]. Ziconotide is included as a possible drug of choice for opioid combination therapy in second- and third-line treatments \[[@CR10]\].

Numerous studies have demonstrated that intrathecal ziconotide reduces the intensity of pain in patients with and without cancer, albeit with a high incidence of adverse effects \[[@CR15], [@CR17]--[@CR23]\]. Recent studies have demonstrated that, at low doses and with careful titration, intrathecal combination therapy with ziconotide and morphine resulted in rapid control of opioid-refractory cancer pain \[[@CR15], [@CR16]\]. However, there is a lack of published data regarding the efficacy and safety of intrathecal ziconotide specifically for the treatment of neuropathic cancer pain.

In this report, we present a case series documenting the efficacy and safety of intrathecal ziconotide added to intrathecal morphine in eight patients with opioid-refractory cancer pain, five of whom had confirmed neuropathic pain.

Case Series {#Sec2}
===========

This retrospective case review included all patients treated with intrathecal ziconotide for neuropathic cancer pain at our pain unit (Hospital Universitario Virgen del Rocío in Seville, Spain) between 2009 and 2012. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients included in the study.

At our pain unit, intrathecal ziconotide is administered alone or in combination with other drugs for all patients with moderate-to-severe chronic pain who, regardless of the cause of pain, do not show an adequate response to other treatment regimens, including intrathecal morphine, or who present with significant adverse events to such treatment. Patients with an estimated survival time less than 3 months are eligible to receive a completely implanted internal pump.

For this case series, neuropathic pain was identified using the Spanish translation of the Douleur Neuropathique (DN4) questionnaire \[[@CR24]\]. The DN4 questionnaire consists of a total of 10 items:7 items related to the quality of pain (burning, painful cold, electric shocks) and its association with abnormal sensations (tingling, pins and needles, numbness, itching), and three related to neurological examination in the painful area (touch hypoesthesia, pinprick hypoesthesia, tactile allodynia). A score of one was given to each positive item and a score of zero to each negative item. The total score was calculated as the sum of all 10 items, and the cutoff value for the diagnosis of neuropathic pain was a total score of 4/10. A visual analog scale (VAS), which ranged from 0 (no pain) to 10 (worst imaginable pain), was used to assess pain intensity.

Between 2009 and 2012, we treated eight patients with cancer pain using intrathecal ziconotide (Table [1](#Tab1){ref-type="table"}). The patients, aged between 45 and 71 years, were predominantly male (*n* = 6; 75%) and had uncontrolled pain, at times with an intense neuropathic pain component, during therapy with high doses of intrathecal morphine plus bupivacaine administered in conjunction with oral adjuvant analgesic therapy, such as amitriptyline, duloxetine, gabapentin, and pregabalin. DN4 scores ranged from 2 to 10. Five patients had a DN4 score ≥4, signifying a diagnosis of neuropathic pain. Baseline VAS scores ranged from 7 to 9.Table 1Baseline demographic and clinical characteristics of the eight patients who received treatment with ziconotide for cancer pain at the Hospital Universitario Virgen del Rocío in Seville, Spain since 2009CharacteristicPatient number12345678Sex (M/F)MMFFMMMMAge (years)4548445863575971Cancer typeRectalSciatic sarcomaMaxillaryRectalColonLungProstateLaryngealDN4 score510484233VAS score89788988*DN* douleur neuropathique, *F* female, *M* male, *VAS* visual analog scale

All patients received a fixed flux intrathecal infusion pump (1 mL/day) with the catheter tip positioned at the T6--T8 level. Treatment was initiated with ziconotide when pain ≥5 on the VAS persisted despite 3 successive 20 % increases in the intrathecal dose of morphine. The five patients with neuropathic pain did not respond to high-dose intrathecal morphine combined with bupivacaine. In all patients, treatment with ziconotide was initiated at 0.5--1.0 µg/day (Table [2](#Tab2){ref-type="table"}), with mean increases of 0.5 µg every 4--7 days, depending on pain control. Ziconotide was added to the intrathecal therapy without discontinuing intrathecal morphine. The maximum final dose of intrathecal ziconotide was 10 µg/day, with the mean final dose being 4.9 µg/day. Duration of treatment ranged from 0.5 to 10 months.Table 2Intrathecal ziconotide and morphine combination therapy dosing informationDosingPatient number12345678Ziconotide dose (μg/day) Initial0.50.50.50.61.00.50.50.5 Final1086653.511Morphine dose (mg/day) Initial1261089111215 Final1261006111215Ziconotide treatment duration (months)10873.5220.51.2

A reduction in pain intensity was noted in all patients 3--5 days after initiating treatment with ziconotide. Compared with VAS scores of 7--9 at baseline, patients had scores ranging from 3 to 6 at the end of treatment (Fig. [1](#Fig1){ref-type="fig"}). Of the eight patients who received ziconotide, four died for reasons unrelated to ziconotide treatment, three required discontinuation of treatment due to adverse effects, and one patient is still receiving treatment.Fig. 1VAS scores of pain intensity at baseline and at the end of treatment with intrathecal ziconotide. *VAS* visual analog scale

Case 1 {#Sec3}
------

This 45-year-old male patient with metastatic rectal cancer and neuropathic pain (DN4 score of 5) was unresponsive to intrathecal morphine 12 mg/day (VAS score of 8). Intrathecal ziconotide 0.5 μg/day was added to therapy in April 2009. The patient was also receiving oral gabapentin 900 mg every 8 h, amitriptyline 25 mg every 24 h, and transdermal fentanyl 200 μg. Intrathecal ziconotide was administered for 10 months with no adverse events. At his last assessment, the patient was receiving ziconotide 10 μg/day plus morphine 12 μg/day, and his VAS score was five. The patient died in February 2010.

Case 2 {#Sec4}
------

This 48-year-old male patient had metastatic sciatic sarcoma with neuropathic pain (DN4 score of 10). He was unresponsive to intrathecal morphine 6 mg/day (VAS score of 9). Intrathecal ziconotide 0.5 μg/day was added to therapy in May 2009. The patient was also receiving oral pregabalin 200 mg every 12 h, amitriptyline 50 mg every 24 h, and oxycodone/naloxone controlled release 60/30 mg every 12 h. Ziconotide was administered for 8 months with no adverse events. At the patient's assessment, his ziconotide dose had been titrated to 8 μg/day, and his morphine dose remained unchanged at 6 mg/day. The patient's VAS score had improved from 9 at baseline to five at the end of treatment. The patient died in January 2010.

Case 3 {#Sec5}
------

This was a 44-year-old female patient with a large maxillary tumor and neuropathic cancer pain (DN4 score of 4). She was unresponsive to intrathecal morphine 10 mg/day (VAS score of 7). Intrathecal ziconotide 0.5 μg/day was added to therapy in June 2009. The patient was also receiving oral gabapentin 900--1200 mg every 8 h, amitriptyline 25 mg every 24 h, and oxycodone/naloxone controlled release 80/40 mg every 12 h. Ziconotide was administered for seven months with no reported adverse events. At the last assessment, the ziconotide dose had been increased to 6 μg/day, and the morphine dose remained unchanged. The VAS score had improved from 7 at baseline to 4 at the end of treatment. The patient died in January 2010.

Case 4 {#Sec6}
------

This 58-year-old female patient with metastatic rectal cancer and neuropathic pain (DN4 score of 8) was unresponsive to intrathecal morphine 8 mg/day (VAS score of 8). She was also receiving pregabalin 300 mg every 12 h, amitriptyline 50 mg every 24 h, and transdermal fentanyl 200 μg/h/day. Intrathecal ziconotide 0.6 μg/day was added to therapy in March 2010. The patient's VAS score improved 50% from 8 at baseline to 4, but ziconotide was discontinued after 3.5 months because the patient developed a neuropsychiatric disturbance that was considered to be related to treatment. At the end of treatment, the patient was receiving ziconotide 6 μg/day. Intrathecal morphine was discontinued during the 3.5-month treatment period.

Case 5 {#Sec7}
------

This 63-year-old male patient with locally advanced colon cancer and neuropathic pain (DN4 score of four) was unresponsive to intrathecal morphine 9 mg/day (VAS score of 8). He was also receiving gabapentin 1200 mg every 8 h, amitriptyline 50 mg every 24 h, and transdermal fentanyl 250 μg/h/day. Intrathecal ziconotide 1.0 μg/day was added to therapy in August 2010. There was a two-point improvement in VAS score, but ziconotide was discontinued after 2 months of treatment (final ziconotide dose 5 μg/day + morphine 6 mg/day) due to confusion and delirium that was considered to be related to treatment. The patient then returned to intrathecal treatment with morphine. Due to continued lack of pain control at high doses of intrathecal morphine and poor tolerance of ziconotide, intrathecal treatment with fentanyl was initiated. As effective pain relief was not achieved after reaching doses of fentanyl 1500 µg/day (VAS score of 8), it was decided that treatment with intrathecal ziconotide should be reinitiated. Ziconotide was started at 0.7 μg and was titrated to a final dose of 4 μg, at which time the patient was also receiving intrathecal fentanyl 1350 μg/day. The patient died in August 2012, 6 months after improvement of pain control was achieved with intrathecal ziconotide and fentanyl (final VAS score of 6) without adverse events requiring discontinuation of the ziconotide infusion.

Case 6 {#Sec8}
------

This 57-year-old male patient with metastatic lung cancer had a DN4 score of 2, indicating that he had nociceptive rather than neuropathic pain. He was unresponsive to intrathecal morphine 11 mg/day, had a VAS score of 9, and was also receiving oral pregabalin 300 mg every 12 h, amitriptyline 50 mg every 24 h, and oxycodone/naloxone controlled release 80/40 mg every 12 h. Intrathecal ziconotide was added to therapy at a starting dose of 0.5 μg/day. The patient's VAS score improved \>50% from 9 at baseline to 4, but ziconotide was discontinued after 2 months (final ziconotide dose 3.5 μg/day + morphine 11 mg/day) because the patient developed confusion that was considered to be related to treatment.

Case 7 {#Sec9}
------

This 59-year-old male patient with metastatic prostate cancer had a DN4 score of three, indicating that his pain was not primarily of neuropathic origin. He had a VAS score of 8 during intrathecal therapy with morphine 12 mg/day. He was also receiving oral gabapentin 900 mg every 8 h, duloxetine 60 mg every 24 h, and morphine extended-release 100 mg every 12 h. The patient began intrathecal ziconotide at a starting dose of 0.5 μg/day, but treatment was discontinued at 15 days (final ziconotide dose 1 μg/day + morphine 12 mg/day) because of adverse events (neurological and gastrointestinal disorders) that were considered to be treatment related. Final VAS score was 6.

Case 8 {#Sec10}
------

This 71-year-old male patient with metastatic laryngeal cancer had DN4 score of three. He had a VAS score of 8 during therapy with intrathecal morphine 15 mg/day. He was also receiving pregabalin 150 mg every 12 h, amitriptyline 25 mg every 24 h, and oxycodone/naloxone controlled release 80/40 mg every 12 h. Intrathecal ziconotide was started at a dose of 0.5 μg/day in July 2012, and the patient was continuing treatment 1.2 months later with no reported adverse events. At his last assessment, the patient was receiving intrathecal ziconotide 1 μg/day and morphine 15 mg/day, and he had a 62.5% in reduction in pain intensity (VAS score of three).

Discussion {#Sec11}
==========

The current case series suggests that addition of intrathecal ziconotide to intrathecal morphine therapy is a successful treatment strategy in patients with cancer pain, including neuropathic pain, refractory to high doses of intrathecal morphine alone. Combination therapy allowed rapid control of pain in our series of eight patients, as demonstrated by a reduction in pain intensity as soon as three to five days after the start of intrathecal ziconotide. All eight patients, five of whom had confirmed neuropathic pain, had a substantial reduction in pain intensity of ≥25%. Two of three patients with a ≥50 % reduction in pain intensity had DN4 scores \<4, indicating that their pain was not primarily of neuropathic origin, and the third patient experienced effective relief of intense morphine-refractory neuropathic pain.

To our knowledge, there are no other published reports of the efficacy of an intrathecal combination of ziconotide and morphine in cancer patients with severe neuropathic pain refractory to high doses of intrathecal morphine. Two studies have demonstrated the efficacy of intrathecal combination therapy with ziconotide and morphine in reducing pain that was inadequately controlled by either intrathecal morphine or ziconotide alone in patients with chronic non-cancer pain \[[@CR22], [@CR25]\]. More recently, intrathecal combination therapy with ziconotide and morphine was shown to be a successful treatment strategy in two studies of patients with cancer pain refractory to high doses of oral opioids \[[@CR15], [@CR16]\]. However, one of these studies involved patients primarily with nociceptive pain from bone metastases \[[@CR15]\], and in the other study results were reported only for the study population as a whole, not specifically for patients with neuropathic pain \[[@CR16]\]. Our case series therefore represents an important addition to the small body of literature documenting the efficacy of an intrathecal combination of ziconotide and morphine in cancer patients with severe opioid-refractory pain.

In addition to recommending ziconotide or morphine alone as a first-line intrathecal treatment option, the PACC considers the combination of morphine plus bupivacaine an option for first-line intrathecal therapy in neuropathic pain \[[@CR10]\]. There is a lack of data on the use of ziconotide in combination with other drugs \[[@CR16]\]. However, as per the clinical practice in our pain unit, there is sound rationale for adding ziconotide to support the effects of intrathecal morphine as part of a multimodal intrathecal analgesia protocol \[[@CR16], [@CR22]\]. The PACC algorithms were created to help guide clinicians in the safe and effective use of intrathecal therapy, but physicians should use their own best clinical judgment in making treatment decisions for their patients \[[@CR10]\]. Our case series helps to demonstrate the effectiveness of intrathecal combination therapy with ziconotide and morphine in cancer patients with neuropathic pain refractory to first-line intrathecal morphine-based therapy in clinical practice. With respect to its safety profile, ziconotide has a narrow therapeutic window, which requires careful titration to determine the lowest possible dose that is therapeutic and sufficiently well tolerated. A high starting dose and/or rapid dose titration can result in adverse effects, including psychiatric abnormalities \[[@CR12]\]. These events frequently require discontinuation of ziconotide and are more likely associated with rapid titration than with the final dose achieved. Current PACC recommendations for intrathecal ziconotide treatment highlight the benefits of a slow titration plan to minimize the risk of adverse events \[[@CR10]\]. To reduce the risk of serious adverse events, we employ a very low starting dosage and a slow titration of intrathecal ziconotide. However, it is necessary to remember that we are dealing with patients with relatively short-life expectancies, intense and frequently increasing pain, and are under significant social pressure for the rapid control of pain. For all these reasons, we are often required to perform rapid titration of ziconotide, with all the consequences that it implies. In the patients documented in this case series, treatment with ziconotide was initiated at 0.5--1.0 µg/day (Table [2](#Tab2){ref-type="table"}), with mean increases of 0.5 µg every 4--7 days, while morphine dose remained stable or was reduced. Four of the eight patients discontinued intrathecal ziconotide because of psychological/neurological adverse events. One of these patients was subsequently able to successfully return to intrathecal therapy with ziconotide. Ziconotide-related adverse events have previously been reported with low doses of ziconotide \[[@CR16]\], and one of our patients discontinued ziconotide because of adverse events when receiving a very low 1 μg/day dose. The other adverse events occurred in patients receiving ziconotide 3.5--6 μg/day. The maximum final ziconotide dose was 10 μg/day. This dose was well tolerated with no reported adverse events.

Conclusions {#Sec12}
===========

The use of combined intrathecal ziconotide and morphine, together with the practice of slow ziconotide titration, promotes successful pain management in cancer patients with severe refractory neuropathic pain. Although ziconotide can be used as a first-line intrathecal treatment option, on the basis of our clinical experience, we recommend adding ziconotide to intrathecal opioid-based therapy in cancer patients with neuropathic pain inadequately controlled by intrathecal morphine alone.
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